MimiVax's Survivin Peptide Vaccine SurVaxM Misses Its Overall Survival Goal in Phase 2b Glioblastoma Trial but Does Better in Patients 65 and Under
MimiVax and Roswell Park Comprehensive Cancer Center reported on October 7, 2026 that in SURVIVE, a randomized, double-blind, placebo-controlled Phase 2b trial in 233 evaluable patients with newly diagnosed glioblastoma at 11 U.S. centers, adding SurVaxM to standard treatment gave a median overall survival of 22.8 months versus 20.3 months on placebo (hazard ratio 0.75, p=0.076), short of statistical significance. In a prespecified group of patients 65 and under, median survival was 24.2 versus 20.2 months (hazard ratio 0.64, p=0.019), and about 42% versus 18% were alive at 30 months or later. SurVaxM is a peptide-mimic vaccine aimed at survivin, a protein found in about 95% of glioblastomas; grade 3 or higher side effects occurred in 48% versus 46% of patients, and MimiVax plans to ask the FDA about faster approval routes.